Polypure clinches PEG deal with BD
This article was originally published in Clinica
Polypure, an Oslo, Norway-based developer and manufacturer of PEG (polyethylene glycol) compounds, has struck a five-year deal with Becton Dickinson to supply its Biosciences subsidiary with monodisperse PEG derivatives. BD Biosciences will use the compounds in its existing and in-development diagnostic products. According to Polypure, its proprietary sample displacement chromatographic purification method enables the company to produce homogenous polymers with a high level of functional integrity. The single molecular weight of monodisperse PEGs also eliminates the characterisation problems of conventional polymer mixtures. These properties, in turn, improve cross-linking, binding and lot-to-lots reproducibility in the resulting diagnostic products, claims the firm.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.